Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06305611

European and North Indian Cohort of KaWasaki dIsease

Kawasaki disease (KD) is currently the leading cause of acquired heart diseases in children in developed countries. Cardiac involvement is the main determinant of the long-term prognosis of these patients, as coronary aneurisms (CAAs) may lead to ischemic heart disease and even sudden death. The current standard of care for KD has consistently reduced CAAs frequency from 25-30% to about 5%. Unfortunately, 10-20% of KD patients results resistant to standard treatment leading to a major risk of cardiac complications. Thus, scoring systems have been constructed in order to identify patients likely to be resistant to IVIG and who may benefit from more aggressive initial therapy. Different scoring scales developed by Kobayashi, Egami et Sano had shown a good sensitivity (77-86%) and specificity (67-86%) in predicting IVIG unresponsiveness in Japanese populations. However, their predictive value was not confirmed by subsequent studies in different ethnic populations. Recently, the French Kawanet group have proposed a IVIG unresponsiveness score that provided good sensitivity and acceptable specificity in a non-Asian KD population even if it was not subsequent validated by an external study. In our study population, the achievement of specificity and sensitivity values for both scores consistent with those reported by the original studies (sensitivity 70% and specificity 80% for Kobayashi and sensitivity 77% and specificity 60% for Kawanet), will be considered a success.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged less than 18 years at diagnosis
  • Diagnosis of KD according to the AHA criteria

Exclusion criteria

  • Patients who do not meet the criteria for KD
  • Patients for which an alternative infectious diagnosis was not investigated and/or excluded.

Treatment and study plan

Primary outcomes

  1. IVIG resistance rate

    Time frame: through study completion, an average of 1 year

    IVIG resistance rate in patients with KD and stratification according to different ethnic groups.

  2. percentage of IVIG-resistant patients

    Time frame: through study completion, an average of 1 year

    percentage of IVIG-resistant patients who met the Kobayashi and KAWANET criteria, and specificity and sensitivity of the criteria within the different ethnic groups.

Study contacts

Contact information is provided by the study sponsor or research team.

Gabriele Simonini

CONTACT

[email protected]

3297973141

Sponsors and collaborators

Lead sponsor

Meyer Children's Hospital IRCCS

Other

Registry information

Official study title

Comparison and Performance of Kobayashi and Kawanet IVIg Resistance Scores in a Multi-centric European and North Indian Cohort of KaWasaki dIsease (the KIWI Study)

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Mar 12, 2024
Registry last updated
Sep 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.